Narwhal Capital Management Purchases 2,150 Shares of Johnson & Johnson (NYSE:JNJ)

Narwhal Capital Management boosted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,016 shares of the company's stock after purchasing an additional 2,150 shares during the period. Johnson & Johnson accounts for approximately 1.3% of Narwhal Capital Management's portfolio, making the stock its 21st biggest position. Narwhal Capital Management's holdings in Johnson & Johnson were worth $14,464,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. IFS Advisors LLC boosted its stake in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after purchasing an additional 100 shares during the period. Highline Wealth Partners LLC bought a new position in Johnson & Johnson during the third quarter worth about $31,000. RPg Family Wealth Advisory LLC bought a new stake in Johnson & Johnson in the third quarter valued at $35,000. Mowery & Schoenfeld Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after acquiring an additional 91 shares during the period. Finally, Activest Wealth Management acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $40,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the company's stock in a transaction dated Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company's stock, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent analyst reports. Bank of America reduced their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, January 23rd. Wells Fargo & Company decreased their price target on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 23rd. Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Thursday, January 23rd. Finally, Barclays raised their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a report on Tuesday. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $170.44.

Johnson & Johnson Stock Performance

NYSE:JNJ traded up $1.72 during mid-day trading on Thursday, reaching $152.87. 2,045,698 shares of the company's stock were exchanged, compared to its average volume of 9,333,421. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The firm has a market capitalization of $368.05 billion, a PE ratio of 22.98, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The business's fifty day simple moving average is $147.73 and its two-hundred day simple moving average is $156.10.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same period in the prior year, the company posted $2.29 EPS. The company's revenue was up 5.3% compared to the same quarter last year. Analysts anticipate that Johnson & Johnson will post 10.56 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. Johnson & Johnson's dividend payout ratio (DPR) is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.